menu
    • menu
    [{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Nestle Health Sciences SA | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LT-02","moa":"Butyrate-producing bacteria","graph1":"Immunology","graph2":"Phase III","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Syneos Health"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PROMETHEUS LABS \/ PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"PROMETHEUS LABS \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PROMETHEUS LABS \/ PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"PROMETHEUS LABS \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vemurafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase IV","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ PROMETHEUS LABS","highestDevelopmentStatusID":"11","companyTruncated":"PROMETHEUS LABS \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Nestle Health Sciences SA | Nestec","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Crown Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Nestec","highestDevelopmentStatusID":"8","companyTruncated":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Nestec"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IL-2`","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"PROMETHEUS LABS \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Ahmad Tarhini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ Ahmad Tarhini","highestDevelopmentStatusID":"8","companyTruncated":"PROMETHEUS LABS \/ Ahmad Tarhini"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Ralph Hauke","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ Ralph Hauke","highestDevelopmentStatusID":"8","companyTruncated":"PROMETHEUS LABS \/ Ralph Hauke"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Shradha Agarwal","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PROMETHEUS LABS \/ Shradha Agarwal","highestDevelopmentStatusID":"1","companyTruncated":"PROMETHEUS LABS \/ Shradha Agarwal"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Leonard Appleman","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ Leonard Appleman","highestDevelopmentStatusID":"7","companyTruncated":"PROMETHEUS LABS \/ Leonard Appleman"}]

    Find Clinical Drug Pipeline Developments & Deals by PROMETHEUS LABS

    Menu

    PROMETHEUS LABS

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Ralph Hauke

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

                            Details : Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 23, 2018

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Ralph Hauke

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LT-02

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Nestle Health Sciences SA | Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Coli...

                            Details : LT-02 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 29, 2016

                            Lead Product(s) : LT-02

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Nestle Health Sciences SA | Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Ahmad Tarhini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Fa...

                            Details : Aldesleukin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 10, 2016

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Ahmad Tarhini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crown Protein

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Nestle Health Sciences SA | Nestec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Th...

                            Details : Crown Protein is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 08, 2016

                            Lead Product(s) : Crown Protein

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Nestle Health Sciences SA | Nestec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin-2

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Dana-Farber Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractor...

                            Details : Interleukin-2 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 19, 2015

                            Lead Product(s) : Interleukin-2

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Dana-Farber Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin-2

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : UT Southwestern Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

                            Details : Interleukin-2 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 11, 2013

                            Lead Product(s) : Interleukin-2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : UT Southwestern Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vemurafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Recipient : Clinigen Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

                            Details : Vemurafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2012

                            Lead Product(s) : Vemurafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Recipient : Clinigen Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Leonard Appleman

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

                            Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2012

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Leonard Appleman

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infliximab

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Shradha Agarwal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

                            Details : Remicade is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 21, 2011

                            Lead Product(s) : Infliximab

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Shradha Agarwal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            PROMETHEUS LABS

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IL-2`

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Providence Health & Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

                            Details : IL-2` is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 15, 2011

                            Lead Product(s) : IL-2`

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Providence Health & Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth